Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLLL-22 is a synthetic curcumin analogue designed to overcome the low bioavailability and poor selectivity of natural curcumin. It is a small molecule that acts as a potent anti-cancer agent by activating the DNA damage pathway, leading to apoptosis. Specifically, FLLL-22 induces DNA double-strand breaks, evidenced by the phosphorylation of H2AX and activation of the p53 pathway, including phosphorylation at Ser15 and Ser392 and upregulation of the downstream target p21. Additionally, it inhibits the phosphorylation of AKT and ribosomal protein S6 and reduces the expression of the anti-apoptotic protein Bcl-2. In preclinical studies, FLLL-22 demonstrated significantly higher potency than natural curcumin in head and neck cancer (Tu212) and lung cancer (H460) cell lines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FLLL-22.